| CAS NO: | 75498-96-3 |
| 包装: | 25mg |
| 市场价: | 810元 |
| Cas No. | 75498-96-3 |
| 别名 | 头孢米诺钠; MT-141 |
| Canonical SMILES | O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSC[C@@H](N)C(O)=O)=O)C1=O)O[Na] |
| 分子式 | C16H20N7NaO7S3 |
| 分子量 | 541.56 |
| 溶解度 | Water: 83.33 mg/mL (153.87 mM) |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of antibacterial activity[1]. Cefminox sodium (MT-141) also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ, upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium (MT-141) also prevents pulmonary arterial hypertension[2]. [1]. Inouye S, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):722-9. [2]. Xia J, et al. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134. |
m.cnreagent.com